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The incidence of malignant melanoma has increased faster than
that of other solid tumours, and, despite successful surgery,
patients with AJCC stage Ilb (T4N0) or stage III (N1) melanoma
remain at high risk of subsequent relapse and death (Mackie et al,
1992). Although many studies have investigated the possible
benefits of adjuvant systemic therapy in this disease, there remains
no universally accepted adjuvant regimen. The use of adjuvant
interferon-a has been shown in at least three studies to improve
the disease-free interval (Rusciani et al, 1997; Grob et al, 1998;
Pehamberger et al, 1998), and possibly also overall survival
(Kirkwood et al, 1996). However the optimum dose and schedule
remain unclear, both in the adjuvant setting and in advanced
disease, where response to systemic interferon is associated with
therapy for at least 3 months, and in doses of at least 1 ´ 106 IU
three times a week (Legha, 1986). Toxicity, however, does appear
to be related to both dose and duration. As a result, the adjuvant
trials conducted have not used the same regimen or dosage, but
either high doses for up to one year, or at least a year’s therapy
with lower doses of interferon. Before any of these studies were
reported, the Scottish Melanoma group conducted a prospective,
randomized trial to test the possible disease-free and overall
survival advantage of a short, 6-month course of low-dose 
interferon-a for patients with high-risk, surgically resected, malig-
nant melanoma. 
PATIENTS AND METHODS 
Patients with histologically proven malignant melanoma were
eligible for randomization if considered at high risk of recurrent
disease. This was defined as a primary lesion of at least 3 mm
Breslow thickness (pT3b or pT4, AJCC Stage II), or following
complete resection of regional lymph involvement detected clin-
ically and confirmed pathologically (N1/N2, AJCC stage III).
Patients were excluded if there was evidence of distant metastatic
disease at presentation, a history of prior malignant disease (except
basal cell carcinoma of the skin or surgically treated early carci-
noma of the cervix), or if they had poor performance status or vital
organ function. The local ethics committees of the participating
hospitals approved the study. 
After giving signed, informed consent, patients were random-
ized in a 1:1 ratio, with stratification by disease stage (AJCC stage
II or III), to observation or treatment with alpha-Interferon 2b for 
6 months. Interferon-a 2b, supplied by Schering-Plough, was
given in a dose of 3 ´ 106 units subcutaneously 3 times a week for
6 months. Patients in both the observation and treatment arms
were seen monthly for 6 months, with liver function tests and chest
X-rays repeated every 3 months. Thereafter patients were followed
up 3 monthly for up to 5 years, and at the institution’s discretion
thereafter. Any clinical suspicion of relapse was confirmed, as
appropriate, by radiological, cytological or histopathological
examination. Date of relapse was taken to be the date of first clin-
ical suspicion of relapse if subsequently confirmed. Follow-up
data on the surviving patients have been obtained from the institu-
tions or the Scottish melanoma group database according to where
the patient was last seen. Cause of death has been assumed to be
due to melanoma if recurrence was either suspected or confirmed,
or unless the treating institution confirmed an alternative proven
cause. 
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The relapse rate was anticipated to be 60% in the control arm
(assumed to be 40% for eligible stage II patients and 80% for stage
III patients). Therefore, if this were to be reduced to 40% in the
treatment arm with an 80% power, 120 patients were required to
be followed to relapse. With these same assumptions therefore, the
target recruitment was 240 patients. However accrual was much
slower than anticipated, despite the inclusion of centres outwith
Scotland, and the study was closed after almost 5 years with just
under 100 patients enrolled. 
RESULTS 
A total of 96 patients were enrolled in this study from 9 centres. 
49 patients were randomized to observation alone and 47 to 6
months’ treatment with interferon-a. 1 patient in the control arm
has been lost to follow-up, and 1 patient randomized to interferon
was found to be ineligible before any treatment was given. For the
remaining 94 patients, the median follow-up is 6.5 years, with a
maximum of 9.7 years. 
Disease-free and overall survival 
Figures 1 and 2 show that both the disease-free and overall
survival appear to be consistently better for the patients treated
with interferon-a as compared with the observation only group.
The median disease-free survival for interferon-treated patients
was 22 months, as compared with 9 months for the control group,
with a concomitant improvement in overall survival from 27 to 39
months for the interferon-a treated patients. Furthermore this
same trend was to be seen for patients with both stage II and stage
III disease (data not shown). However these apparent differences,
although if real of clinical significance, are not statistically signi-
ficant. There was in addition no significant difference in the site of
first relapse between the two groups. When analysing the disease-
free survival data at early time points, statistically significant
differences in favour of interferon are to seen at 6, 12, 18 and 24
months (P < 0.05, P < 0.025, P < 0.025 and P = 0.05, respect-
ively). Figure 3 therefore shows the hazard rate for disease-free
survival at 6-month intervals for the whole duration of available
follow-up, confirming a clear early benefit for adjuvant interferon-a
extending for up to 24 months from trial entry. When considering
the patients with stage II and stage III disease separately, this early
difference in hazard rate for interferon-a treated patients is also
seen (data not shown). Furthermore, Figure 3 suggests that there
might be a further benefit for adjuvant interferon-a in the form of
reduced hazard rate for late relapse, although this observation is
based on data from only 6 patients. 
Toxicity 
Of the 46 eligible patients randomized to receive adjuvant inter-
feron, 29 (63%) completed the 6 months as per protocol. 3 (7%)
experienced a dose reduction, 2 for neutropenia and 1 for drug-
related fever. Treatment was stopped in 13 (28%) following
confirmed recurrence, including one who had experienced a dose
reduction. 2 patients (4%) randomized to the treatment arm did not
receive treatment, but have been included in the analyses on an
intent-to-treat basis. The treatment was in general well tolerated,
with patients able to continue in full-time work. Paracetamol was
given as prophylaxis for the most frequently reported side effects
of myalgia and chills, and was in general discontinued early in the
course of therapy. 
DISCUSSION 
This study demonstrates that adjuvant interferon-a, given at low
dose for only 6 months, appears to have some impact on high-risk
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Figure 1 Disease-free survival by treatment arm (Observation n = 48,
Interferon n = 46). c2 = 1.9, P > 0.1 
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Figure 2 Overall survival by treatment arm (Observation n = 48, Interferon
n = 46). c2 = 1.5, P > 0.2 
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Figure 3 Hazard ratio for relapse by time, with an interval of 6 months 1148 DA Cameron et al 
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stage II and III melanoma. There was an improvement in disease-
free survival maintained for more than a year beyond the cessation
of a well-tolerated adjuvant therapy. The lack of any statistically
significant benefit on long-term disease-free and overall survival
could in part be a result of the disappointing recruitment, resulting
in a trial underpowered to detect the hypothesized treatment effect.
If the planned number of patients had been accrued, and the same
improvement in disease-free survival seen, then statistical signific-
ance could have been achieved. Therefore, before concluding that
the study is clinically negative, the data need to be considered in
the context of previously reported, larger, studies. 
The first data to suggest that adjuvant interferon could impact
on the natural history of malignant melanoma came from the
WHO adjuvant study. In this trial, 426 evaluable patients with
involved lymph nodes were randomized to either an observation
group or 3 years’ treatment with Interferon-a 2a at the dose of 
3 MU day–1 thrice weekly (Cascinelli, 1995). However more
recent analyses, with longer follow-up, have not confirmed the
disease-free survival benefit that had been reported earlier
(Cascinelli, 1999). In contrast, the data from the ECOG E1684
study demonstrate a clear disease-free and an apparent survival
advantage for the use of high-dose interferon-a in high-risk
melanoma, using a one-sided P value, the justification for which is
not given in the text (Kirkwood et al, 1996). This study random-
ized 287 patients with stage II and III disease between observation
only, and an experimental arm comprising 4 weeks of 20 MU
interferon-a given intravenously 5 days week–1, followed by 48
weeks of 10 MU interferon-a given subcutaneously 3 times a
week. The majority of patients were unable to complete the
schedule, and there were 2 toxic deaths on the treatment arm.
There was a clear disease-free survival advantage for interferon-a,
but using the gold standard of an intention-to-treat analysis and a
two-sided test, the difference in overall survival has a P value
between 0.05 and 0.06. Furthermore, 89% of patients had stage III
disease, and thus no conclusions can be drawn from this study
about the management of high-risk node-negative melanoma. In
contrast, 2 studies have reported a disease-free survival advantage
for prolonged low-dose interferon. A French study randomized
489 eligible patients with stage II disease between observation and
18-months of 3 MU interferon-a given subcutaneously 3 times a
week (Grob et al 1998). There was a significant disease-free
survival advantage for the patients who received interferon-a, and
a trend for an improvement in overall survival with a two-sided P
value between 0.05 and 0.06. The Austrian study randomized 311
patients with stage II disease between observation and one year’s
treatment with 3 MU interferon-a (Pehamberger et al, 1998). The
authors reported a clear disease-free survival advantage for the
patients given interferon, but there were insufficient deaths
observed during the relatively short follow-up period to evaluate
any effect on survival. The next ECOG study, E1690, compared
the high-dose Kirkwood regimen with 2 years of 3 MU interferon
given subcutaneously 3 times a week, and an observation only
group (Kirkwood et al, 2000a). In contrast to the earlier E1684
study, E1690 has not demonstrated a survival advantage for either
treatment arm as compared to the control observation arm, but has
reported a statistically significant disease-free survival advantage
for the high-dose regimen as compared with the observation arm
(hazard ratio 1.28, P = 0.05). Furthermore, an early analysis of
data from the subsequent ECOG trial 1694, which compares 2
years’ high-dose interferon with a ganglioside GM2 vaccine, again
suggests a survival advantage for interferon over the alternative
therapy (hazard ratio 1.52, P < 0.01) (Kirkwood et al, 2000b).
Finally, it must be noted that the ECOG studies employed inter-
feron-a-2b, the compound used in this study, whereas in the
French and Austrian studies, patients were treated with the alterna-
tive form, interferon-a-2a. Whether there is a significant differ-
ence in effect between these two forms of interferon-a remains
however to be proven. 
The studies that have reported since the Scottish study was
closed to recruitment consistently demonstrate a clear improve-
ment in disease-free survival for treatment with interferon-a, 
and furthermore 2 studies, one each with low-and high-dose 
interferon-a, report an improvement in overall survival with a
two-sided P value between 0.05 and 0.06 (Kirkwood et al, 1996;
Grob et al, 1998). Furthermore, the magnitudes of these improve-
ments are well within the confidence intervals for the observed
disease-free and overall survival rates in the current study. The
pattern over time seen for the hazard-rate for relapse with 6
months low-dose interferon-a in the Scottish study (see Figure 3),
is similar to that reported by Grob for 18 months of the same treat-
ment, with a significant early effect from therapy. However the
current study reports longer-term follow-up data, and there is the
suggestion in both stage II and stage III disease for a late benefit.
The only other study to report similar long follow-up is the E1684,
and although there is no such trend overall, a possible additional
late difference in hazard rate is seen in some sub-groups, including
the small number of patients with stage II disease. The biological
rationale for these observations would be that there is an imme-
diate reduction in relapse consequent upon the cytotoxicity of
interferon-a, whereas one might anticipate that any immuno-
modulant effect on microscopic disease would be better seen in the
pattern of late relapse. 
Thus the data in the Scottish adjuvant melanoma trial are consist-
ent both with the results of the other adjuvant studies that have
been fully reported to date, and with the notion that adjuvant 
interferon-a gives at least a disease-free survival advantage for
patients with both stage II and stage III disease. The optimal dura-
tion of therapy remains unclear, and it cannot be concluded with
certainty that either low- or high-dose interferon-a gives a definite
survival advantage, so there remains no standard adjuvant therapy.
The results of the larger trials randomizing patients between low or
intermediate dose interferon-a and observation, such as AIM-High
and the EORTC trials, will be better powered than the prior studies
to answer this all-important question of a possible survival advan-
tage for adjuvant interferon in the treatment of high-risk surgically
resected malignant melanoma. 
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